| Home > Publications database > Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. |
| Journal Article (Erratum/Correction) | DKFZ-2025-02152 |
; ; ; ; ; ; ; ; ; ; ;
2025
MDPI
Basel
Abstract: Error in FigureIn the original publication [1], there was a mistake in Figure 2C right as published. An error occurred during figure assembly duplicating part of the figure. The corrected Figure 2C right appears below.Cancers 17 03181 g002Figure 2. DYRK1A knockout enhances radiotherapy efficacy in pancreatic cancer. (A) Western blot of TB32047 and MIA PaCa-2 cells transfected with DYRK1A sgRANs or non-targeting control. (B) A clonogenic assay of TB32047 (left) and MIA PaCa-2 (right) cells with DYRK1A KO and control sgRNA cells was performed after irradiation with different doses of X-rays. The colony numbers were counted and normalized. Data are presented as means of three independent experiments (n = 3). *, p < 0.05; **, p < 0.01; *** and p < 0.001 by 2-tailed unpaired Student’s t test. (C) TB32047 (left) and MIA PaCa-2 (right) single clones and control cells were treated with different doses of radiation followed by clonogenic assays. Representative images of three independent experiments (n = 3) are shown. (D,E) Flow cytometry-based apoptosis analysis of TB32047 (D) and MIA PaCa-2 (E) control and DYRK1A KO single clones irradiated with 5 Gy X-rays after 24 h. Representative images of three independent experiments (n = 3) and statistical analysis are shown. **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001 by 2-tailed unpaired Student’s t test. ns. not significant.The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
|
The record appears in these collections: |